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Abstract. The feasibility of using a sensitive polymerase chain reaction (PCR) to evaluate malaria vaccines in small
group sizes was tested in 102 adult Gambian volunteers who received either the malaria vaccine regimen FP9 ME-
TRAP/MVA ME-TRAP or rabies vaccine. All volunteers received the antimalarial drugs primaquine and Lapdap plus
artesunate to eliminate malaria parasites. Volunteers in a further group received an additional single treatment with
sulfadoxine-pyrimethamine (SP) to prevent new infections. There was substantially lower T-cell immunogenicity than in
previous trials with this vaccine regimen and no protection against infection in the malaria vaccine group. Using the
primary endpoint of 20 parasites per mL, no difference was found in the prevalence of low-level infections in volunteers
who received SP compared with those who did not, indicating that SP did not reduce the incidence of very low-density
infection. However, SP markedly reduced the incidence of higher density infections. These findings support the feasi-
bility and potential of this approach to screen pre-erythrocytic vaccines for efficacy against infection in small numbers
of vaccinees in endemic areas.
INTRODUCTION
Increased funding for malaria vaccine development, ad-
vances in vaccine technology and the sequencing of the Plas-
modium falciparum genome have led to an increasing number
of candidate malaria vaccines reaching the phase of clinical
evaluation. Although pre-erythrocytic vaccines can be tested
using sporozoite challenge with P. falciparum in non-immune
volunteers,1–3 it is uncertain how well this model will predict
vaccine efficacy in populations exposed to natural infection
with genetically heterogeneous P. falciparum and provide evi-
dence of efficacy in phase II studies in populations exposed to
natural challenge that may be required before proceeding to
a large phase III trial. RTS,S/AS02A, the most widely studied
malaria vaccine, has consistently protected 30–45% of volun-
teers challenged experimentally with sporozoites about 2
weeks after final vaccination. Efficacy of this vaccine against
natural challenge with heterologous parasite strains in semi-
immune adults in the field was 34% using a time-to-patent
infection analysis4 and 30% and 35% after 6 and 18 months,
respectively, against clinical malaria in Mozambican chil-
dren.5,6 These results for RTS,S/ASO2A suggest that for this
vaccine, efficacy in the field against patent infection is similar
to that measured in the experimental challenge model. A
randomized trial of DNA-MVA vaccination undertaken in
semi-immune adults in The Gambia in 2002 showed no sig-
nificant efficacy against infection,7 although the same vacci-
nation regimen resulted in significantly delayed time to par-
asitemia compared with unvaccinated controls in challenge
experiments with a heterologous strain in Oxford and fully
protected one of eight non-immune volunteers.8
As long as uncertainty remains about the correlation be-
tween the results obtained with the experimental sporozoite
challenge model and results obtained under conditions of
natural challenge, field-efficacy trials will continue to play an
essential part in the early evaluation of candidate pre-
erythrocytic vaccines. Because the power of a trial to detect
efficacy depends on the number of events observed, more
sensitive methods of detection would allow smaller sample
sizes to be used. In semi-immune populations, most infections
are cleared by blood-stage immunity prior to patency. Com-
parison of estimates of entomological inoculation rates with
observed infection rates detected by peripheral blood micros-
copy in villages near the town of Farafenni, The Gambia, in
2002 suggested that the great majority of infectious bites did
not lead to infections detectable by blood film.7 However,
many blood-stage infections may have been missed because
of the low sensitivity of microscopy, which has a lower limit of
detection of ∼10–50 parasites per L.9 Polymerase chain re-
action (PCR) assays that increase the sensitivity of detection
of blood-stage malaria infections by at least a hundred fold
compared with traditional microscopy have recently been de-
veloped.1,3,10
Although PCR monitoring is being used increasingly in the
context of malaria vaccine volunteer challenge studies in de-
veloped countries,11–14 few such studies have been conducted
in endemic areas. In endemic areas, many malaria infections
in adults fail to reach a parasite density that is high enough to
be detected by microscopy, and the sample size and hence the
cost of efficacy trials is typically large, requiring hundreds of
volunteers per study arm.5,7 If low-density infections could be
detected reliably prior to blood-stage clearance, then the
sample size needed for the evaluation of pre-erythrocytic vac-
cines could be reduced. We have, therefore, undertaken a
randomized trial using repeated blood sampling with PCR
monitoring to evaluate the feasibility of this method for vac-
cine evaluation and to make a preliminary assessment of the
safety, immunogenicity, and efficacy against malaria infection
of the FP9 ME-TRAP/MVA ME-TRAP candidate malaria
vaccine, which has shown significant efficacy in volunteer
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challenge studies in the UK11,15 and promising immunogenic-
ity in Gambian adults.16
MATERIALS AND METHODS
Study area and study population. The study took place in
nine villages east of Farafenni, The Gambia, from June to
October 2004, the time of year when the incidence of malaria
in The Gambia is highest. The entomological inoculation rate
in the study area was ∼10–50 infectious bites per year. Vol-
unteers of age 15–45 years, identified using the demographic
surveillance system (DSS), were invited to take part in the
study after prior consultations with local civil and religious
leaders. Experienced field workers gave detailed explanations
of the nature of the trial in English and in their respective
local languages, and written consent was obtained. In the case
of volunteers of age 15–17 years, written informed consent
was also obtained from a parent or guardian. Prior to screen-
ing, the age and identity of each volunteer were checked, and
a trained member of the study team provided pre-HIV test
counseling. Screening involved a thorough physical examina-
tion as well as laboratory evaluation. The latter included mea-
surement of a full blood count (FBC), packed cell volume
(PCV), plasma creatinine, and alanine amino transferase
(ALT) concentrations as well as HIV 1 and 2 screening by
ELISA (Capillus HIV1/HIV2 Kit, Trinity Biotech PLC, Ire-
land). A glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency test (visual colorimetric assay, Sigma Diagnostics, US)
was carried out because of the risk of hemolysis when pri-
maquine is given to volunteers who are G6PD deficient. Vol-
unteers were considered eligible if they had no clinically sig-
nificant disease. Exclusion criteria included a low PCV (<
30%), raised plasma creatinine (> 130 mol/L), raised ALT
concentration (> 42 IU/L), G6PD deficiency, simultaneous
participation in another clinical trial, blood transfusion in the
month prior to vaccination, previous experimental malaria
vaccination, administration of another vaccine within 2 weeks
of vaccination, allergy to any previous vaccination or to sul-
fadoxine-pyrimethamine (SP), a history of splenectomy, and
any treatment with immunosuppressive drugs. Eligible volun-
teers were assigned a unique study number and a photo iden-
tity card.
Study vaccines. Details of study vaccines have been de-
scribed elsewhere.14 The malaria DNA sequence known as
ME-TRAP encodes the entire TRAP antigen of the T9/96
strain of P. falciparum and a string of epitopes from six pre-
erythrocytic P. falciparum antigens. The sequence is ex-
pressed either in fowlpox (FP9 ME-TRAP) or in modified
vaccinia virus Ankara (MVA ME-TRAP). The vaccines were
manufactured according to good manufacturing practice by
Impfstoffwerk Dessau-Tornau (IDT, Rosslau, Germany).
FP9 ME-TRAP was administered at a dose of 1 × 108 plaque-
forming units (PFU/mL) given as 2 intradermal injections into
the skin overlying the right or left deltoid muscle. MVA ME-
TRAP was administered at a dose of 1.5 × 108 PFU/mL given
as 2 intradermal injections into the skin overlying the deltoid
muscle of the non-dominant arm. Rabies vaccine was admin-
istered as two 0.1 mL intradermal injections into the skin
overlying the deltoid muscle.
Study design. This was a randomized, open, controlled trial
that compared the efficacy of the malaria vaccine regimen
with a control (rabies) vaccine. Half the volunteers in the
rabies vaccine group received a single treatment with sulfa-
doxine-pyrimethamine (SP) prior to the surveillance period
to provide a “positive” control group in whom protection
against malaria could be expected for a period of several
weeks. P. falciparum remains sensitive to SP in the study area.
Allowing for a steady rate of drop-out during follow-up
amounting to total of 20% of subjects by the end of the trial,
the trial had at least 80% power (using 2-sided 5% signifi-
cance level) to detect a difference in time to infection be-
tween vaccine and control groups if the vaccine efficacy was
at least 60%, and at least 70% of the control group volunteers
developed parasitemia during the trial. A randomization list
was generated using a block size of 6; individuals were allo-
cated to treatment groups in a 1:1:1 ratio. Pre-prepared ran-
domization envelopes, numbered 1–120, contained slips with
the treatment assignment. On the day on which the first dose
of vaccine was due, treatments were assigned according to
pre-prepared numbered envelopes. For logistic reasons, 30
volunteers were enrolled in the malaria vaccine group, 37 in
the rabies vaccine plus SP group, and 35 in the rabies-alone
group (Figure 1). All volunteers were scheduled to receive 3
doses of either malaria or rabies vaccine given 4 weeks apart.
After vaccination, volunteers were observed for 1 hour to
detect any immediate side effects and given a course of anti-
pyretic (paracetamol, 500 mg, 3 times a day) to take if re-
quired. Field workers made home visits on days 1 and 2 after
vaccination, and volunteers were seen by the study physician
on days 7 and 28 after each vaccination to record any adverse
events on a standard diary card. All volunteers received the
antimalarial drug primaquine (30 mg) 7 days before the final
vaccination and a 3-day course of Lapdap (2 mg/kg body
weight of chlorproguanil and 2.5 mg/kg body weight of dap-
sone given as standard adult dose) plus artesunate (4 mg/kg
body weight divided into 3 doses) commencing on the day of
final vaccination to eliminate asexual- and sexual-stage ma-
laria parasites from peripheral blood before surveillance com-
menced 7 days later. Both dapsone and chlorcycloguanil have
half-lives of ∼30 hours, so drug levels would have fallen well
below inhibitory levels before surveillance started. Clearing
existing blood-stage parasites in this manner facilitated the
detection of new infections resulting from the bite of an in-
fectious mosquito during the surveillance period. In addition,
volunteers in the rabies + SP group received a single treat-
ment of SP when the surveillance period began.
Vaccine efficacy was determined by comparing the inci-
dence of infections in the malaria vaccine and rabies vaccine
groups. During the 28-day surveillance period, daily finger-
prick blood samples were obtained to provide 0.5 mL of
blood for PCR analysis and for preparation of two blood
films. Laboratory staff who read blood films or conducted
immunoassays and PCR analysis were blind to the group al-
location of volunteers until after approval of the analysis plan
by the data safety monitoring board (DSMB).
Volunteers could contact a study nurse and a physician at
anytime during the course of the study if they had concerns
about their health. The study was conducted in accordance
with the Declaration of Helsinki principles for the conduct of
clinical trials, the International Committee of Harmonization
Good Clinical Practices Guidelines, and with the local rules
and regulations of the UK Medical Research Council unit in
The Gambia and monitored by independent external moni-
tors. An independent DSMB, including a local safety moni-
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tor, provided oversight for the trial. The Gambia government/
MRC, London School of Hygiene & Tropical Medicine, and
the University of Oxford ethics committees approved the
study. The trial was registered with ClinicalTrials.gov, a ser-
vice of the US National Institutes of Health, and allocated the
trial number NCT00121823.
Laboratory analysis. Duplicate thick blood films were
stained with Giemsa and examined by two microscopists.
When discrepancies occurred in the readings, a senior micros-
copist was available to confirm the presence of parasitemia.
Blood samples were collected 1 week after the final vaccina-
tion and at the end of the study for estimation of FBC, PCV,
ALT, and creatinine. Full blood counts were done using a
Medonic CA620 cell analyzer (Medonic, Stockholm, Swe-
den). ALT and creatinine were measured using a Bio-
Merieux visual analyzer (Bio-Merieux, Craponne, France).
Immunogenicity. Ex vivo IFN- ELISPOT assays were car-
ried out on days 0, 63, and 150 as described elsewhere.7,11,15,18
The AutoImmun Diagnostika ELISPOT Plate Reader
(Strassberg, Germany) was used for automated counting of
spots. The results were expressed as the number of spot form-
ing units (SFU) per million peripheral blood mononuclear
cells (PBMC). The SFU for a given stimulant was calculated
by subtracting the average of the two negative control wells
(cells plus culture medium) from the average of the two du-
plicated stimulant wells (cells plus culture medium plus stimu-
lant). A “positive” response was reported if the SFU were
greater than the background and over 50 SFU per million
PBMC. Phytohemagglutinin (PHA) was used as a positive
control. All peptides were used at a concentration of 25 g/
mL. A single pool contained all ME peptides. Six peptide
pools were used to stimulate the cells. These contained 7–10
FIGURE 1. Trial profile.
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20-mer peptides overlapping by 10 amino acids and spanning
the entire TRAP antigen from the T9/96 strains of P. falci-
parum (Pool 1 amino acids 1–110; Pool 2 101–210; Pool
3 201–310; Pool 4 301–395; Pool 5 385–495; and Pool
6  486–559).
DNA preparation. Finger-prick blood samples for PCR
analysis were collected in EDTA Vacutainer tubes. Samples
were stored at 4°C for up to 72 hours. The blood volume was
recorded, and the samples were flicked to check for blood
clots. Large sample volumes were reduced to 0.5 mL after
mixing to ensure that whole blood was removed and not
plasma alone. Whatman 24-well, double-layer filter plates
were used to remove leukocytes from the blood, as described
previously, while allowing erythrocytes to pass through.3
Samples under 250 L were not filtered as it was thought that
a low number of parasites might be lost on the filter mem-
brane. Clotted samples were not filtered. Filtered blood was
stored at −20°C until DNA extraction. DNA was extracted
from the filtered, clotted, or low-volume samples using the
QIAamp DNA Mini Blood Kit (Qiagen Ltd., Crawley, UK)
with adaptations.3 DNA samples were frozen at −20°C until
PCR analysis.
Quantitative real-time PCR. Parasitemia was detected by
quantitative real-time PCR using a Rotorgene 3000 machine
(Corbett Research, Sydney, Australia) and Qiagen Quanti-
tect SYBR Green I PCR kit, as described elsewhere.3
Samples were analyzed for the presence of the parasite multi-
copy 18S (small sub-unit) ribosomal RNA genes. Parasite
density was quantified using a standard curve of known par-
asitemia with a limit of sensitivity of 20 parasites/mL.3
Statistical analysis. An analysis plan was approved by the
DSMB before analysis of data commenced. Primary analysis
of efficacy was according to protocol (limited to subjects who
received the full course of vaccination). The time at risk for
each volunteer was considered to start 7 days after the third
dose of vaccine had been given and to end either on the day
of first positive PCR blood sample or, if none of the samples
were positive, on the day the last sample was collected. The
primary endpoint, set before analysis was undertaken, was
time to first parasitemia by PCR with a density 20 parasites/
mL, followed by a second positive result on the next sampling
day. This endpoint was the limit of parasite detection by PCR
and the most sensitive assay of malaria infection. Secondary
analyses were time to first infection with parasite density 
100 or  1000 parasites/mL and also time to first infection at
these densities followed by a second positive result. Vaccine
efficacy (VE) was defined as VE  1 − R, where R is the
hazard ratio (malaria vaccine group:rabies group) estimated
using the Cox proportional hazards model including all the
covariates. A 95% confidence interval for VE was computed.
The primary analysis included adjustment for important co-
variates that were recruitment center, age, bed net use, and
the condition of the net. Statistical analysis of the cell-
mediated responses induced by vaccination was done using
the Wilcoxon signed rank test or the Mann-Whitney U test.
RESULTS
Volunteers. We screened 168 volunteers, of whom 41 were
excluded (3 due to low PCV, 28 were G6PD deficient, 2 had
a positive HIV test, 6 had clinical abnormalities, and 2 had
raised ALT concentrations) and 127 were found to be eligible
for the study. Of the eligible volunteers, a total of 102 volun-
teers were recruited into the study and received the first vac-
cination. Ninety-three and 94 of the recruited volunteers re-
ceived the second and third doses of vaccine respectively.
Eighty-seven volunteers received all 3 doses (1 volunteer
withdrew consent, and 14 others had traveled out of the area
at the time of vaccination). Ninety volunteers commenced the
28-day follow-up period (Figure 1). The age range of volun-
teers 25–45 years was comparable (Table 1). Over the 28-day
follow-up period, finger-prick blood samples were obtained
each day from an average of 70% of volunteers. Compliance
among the study volunteers during the surveillance period
was high, with 25 volunteers giving samples on all 28 days
(24.5%) and 59 volunteers missing only 5 or fewer time points
(57.8%). Eleven vaccinated volunteers gave no samples at all,
and the same number gave fewer than 10 samples.
Vaccine safety and reactogenicity. All vaccines were safe
and well tolerated. All hematological and biochemical param-
eters remained within normal range for the duration of the
study. All solicited adverse events (systemic and local) were
assessed as mild or moderate and of short duration. No seri-
ous adverse event was recorded. Generally, there was a sig-
nificantly greater occurrence of solicited adverse events in the
malaria vaccine group compared with volunteers in the rabies
group (Table 2). There were more episodes of limited arm
motion in volunteers after the first dose of the malaria vaccine
(23% [7/30]) compared with the control group (1% [1/72], P
< 0.001). This side effect was present in 1 of 28 volunteers
after the second dose but was not recorded after the third
dose of the malaria vaccine. Dry blisters and pain at the site
of injection occurred in 53% (16/30) and 50% (15/30) of vol-
unteers after the first dose of the malaria vaccine, but the
prevalence of these side effects fell to 24% (7/29) and 21%
(6/29), respectively, after the third dose.
Immunogenicity after prime-boost vaccination with FP9
and MVA. IFN- responses to TRAP were measured by ex
vivo ELISPOT on freshly isolated PBMC 7 days after the
final vaccination in volunteers in the malaria vaccine and ra-
bies groups. Initial samples from a group of 6 randomly se-
lected volunteers were analyzed before vaccination to obtain
a baseline reading (median values, Figure 2). One volunteer
was excluded from the analysis due to an unacceptably high
background level (cells plus culture medium well  67 SFU
TABLE 1
Demographic characteristics of volunteers enrolled in the trial
Characteristic
Malaria vaccine
group
(N  30)
n (%)
Rabies + SP group
(N  37)
n (%)
Rabies group
(N  35)
n (%)
Total
(N  102)
Ethnic group
Wollof 4 (13%) 14 (38%) 13 (37%) 31
Mandinka 21 (70%) 20 (54%) 18 (51%) 59
Fula 5 (17%) 3 (8%) 4 (11%) 12
Age (years)
15–24 16 (53%) 22 (59%) 21 (60%) 59
25–45 14 (47%) 15 (41%) 14 (40%) 43
Bed net
Good 3 (10%) 1 (3%) 5 (14%) 9
Fair 6 (20%) 10 (27%) 13 (37%) 29
Poor 10 (33%) 10 (27%) 6 (17%) 26
No bed net 11 (37%) 16 (43%) 11 (31%) 38
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per million PBMC). Overall vaccine immunogenicity was un-
expectedly low compared with previous studies of this regi-
men in the UK11,15 and The Gambia.16 Although a significant
difference was seen between the malaria vaccine and rabies
groups (Wilcoxon signed ranks test: P 0.044), the responses
are ∼10-fold lower than in previous studies with this regimen
and well below the level associated with protection in volun-
teer challenge studies.11 Seven of 18 volunteers responded
with an ex vivo ELISPOT above the group average. The re-
sponse to different peptide pools in the ELISPOT assay was
measured. TRAP Pool 1 induced the highest response, which
was significantly different from Pools 4 and 5 (Wilcoxon
signed ranks test: Pool 4, P 0.006; Pool 5, P 0.006, Figure
3). Pool 4 contained the least immunogenic peptides, and was
significantly less immunogenic than Pools 1, 2, or 3 (Wilcoxon
signed ranks test: Pool 1, P 0.006; Pool 2, P 0.004; Pool
3, P  0.002).
Drug treatment. Ninety-three volunteers (91%) received a
single dose of primaquine, and 84 (82%) received all 3 doses
of Lapdap plus artesunate. Ninety-two percent (34/37) of vol-
unteers allocated to the rabies + SP group received the SP 1
day prior to the start of the 28-day follow-up period. The 3
volunteers who did not receive SP were not included in the
PCR analysis.
One volunteer had a parasitemia of ∼12,000 parasites/mL
on the first day of surveillance and was excluded from further
participation in the study and the analysis. Drug treatment
was successful in eliminating blood-stage parasites in the re-
maining volunteers.
PCR analysis. Twenty percent of the total number of blood
samples (2033) analyzed were PCR positive. Overall, 71% of
the volunteers had one positive PCR result > 20 parasites/mL,
and 55% had two positive PCR results above this level. The
results of PCR analysis in the study groups at parasite densi-
ties of 20, 100, and 1000 parasites/mL are shown in Kaplan-
Meier plots (Figure 4a–c). There was no significant difference
in time to first infection between the malaria vaccine and the
(Figure 4a) rabies groups (adjusted hazard ratios 1.1, 1.75,
and 2.3; P  0.735, 0.184, and 0.056, respectively). Thirty-
three volunteers had occasional low-level parasitemia, or
“blips,” followed by negative PCR results (maximum,
2,521,353 parasites/mL; minimum, 22 parasites/mL; geometric
mean, 152 parasites/mL; median, 87 parasites/mL); these were
mainly in the rabies + SP group (malaria vaccine  7; rabies
+ SP 20; rabies 6). Overall, 28 volunteers remained PCR
negative throughout the 28-day follow-up. They were mostly
in the rabies-vaccinated control groups (malaria vaccine 4;
rabies + SP  12; rabies  11).
TABLE 2
Frequency of adverse events after each vaccination
Adverse effects FP9 dose 1 Rabies dose 1 FP9 dose 2 Rabies dose 2 MVA (after 2 doses of FP9)
Rabies
dose 3
Headache 4 (13%) 3 (10%) 2 (8%) 6 (9%) 9 (31%) 7 (11%)
(4, 31) (0, 10) (1, 24) (3, 19) (15, 51) (5, 21)
Fever 0 0 0 0 0 0
(0, 10) (0, 4) (0, 10) (0, 4) (0, 10) (0, 5)
Malaise 2 (6%) 2 (3%) 1 (4%) 0 7 (24%) 11 (19%)
(1, 22) (0, 10) (0, 18) (0, 4) (10, 44) (9, 29)
Nausea or vomiting 0 2 (3%) 0 1 (2%) 6 (21%) 5 (12)
(0, 10) (0, 10) (0, 10) (0, 8) (8, 40) (3, 17)
Pain 15 (50%) 4 (6%) 13 (46%) 4 (6%) 6 (21%) 1 (2%)
(31, 69) (2, 14) (28, 66) (2, 15) (8, 40) (0, 8)
Discoloration 19 (63%) 19 (26%) 16 (57%) 22 (33%) 8 (28%) 6 (9%)
(44, 80) (17, 38) (37, 76) (22, 46) (13, 47) (4, 19)
Itching 8 (27%) 5 (7%) 8 (29%) 4 (6%) 2 (7%) 2 (3%)
(12, 46) (2, 16) (13, 49) (2, 15) (1, 23) (0, 11)
Induration 30 (100%) 25 (35%) 24 (86%) 23 (35%) 24 (83%) 27 (42%)
(90, 100) (24, 47) (67, 96) (24, 48) (64, 94) (30, 55)
Blistering 16 (53%) 3 (4%) 7 (25%) 0 7 (24%) 0
(34, 72) (1, 12) (11, 50) (0, 4) (10, 44) (0, 5)
Limited arm motion 7 (23%) 1 (1%) 2 (3%) 0 0 0
(10, 42) (0, 8) (0, 18) (0, 4) (0, 10) (0, 5)
Total 30 72 28 66 29 64
Note: Adverse events were assessed 1 hour and 1, 2, 7, and 28 days after each vaccination. Observations were made in 30 volunteers in the malaria vaccine group (FFM), in 37 in the rabies
+ SP group, and in 35 in the rabies group who received at least one dose of vaccine. Results are presented as n (%) and 95% CI.
TABLE 3
Incidence of parasitemia detected by PCR in the two vaccine groups
Positive defined as Vaccine % Positive Hazard ratio (95% CI) P value
Hazard ratio adusted
for covariates (95% CI)* P value
 20 ppmL ME-TRAP 74% (17/23) 1.14 (0.56, 2.3) 0.709 1.12 (0.53, 2.4) 0.776
Rabies 56% (14/25) 1 1
 100 ppmL ME-TRAP 70% (16/23) 1.64 (0.74, 3.6) 0.219 1.75 (0.77, 4.0) 0.184
Rabies 42% (10/24) 1 1
 1000 ppmL ME-TRAP 81% (17/21) 2.0 (0.92, 4.4) 0.082 2.3 (0.98, 5.6) 0.056
Rabies 42% (10/24) 1 1
* Adjusted for effects of age, center, bed net use, and ethnic group.
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Blood films. Duplicate blood films were prepared at the
same time as samples were collected for PCR analysis. Over-
all 97/2070 (4.7%) blood films were positive for P. falciparum
asexual parasites. P. falciparum asexual parasites were de-
tected in 49/399 (12.3%) samples positive at the 20 parasites/
mL threshold in the PCR assay, in 48 of 316 positive (15.2%)
at the 100 parasites/mL threshold, and in 41 of 178 (43.4%)
positive using the 1000 parasites/mL threshold. Thirty-three
of the 1634 samples that were negative by PCR were blood-
film positive. This represents a 2.0% discrepancy between the
PCR and blood-film results. Only 5 cases of clinical malaria
were recorded during the follow-up period (1 in the rabies +
SP and 4 in the malaria vaccine groups, respectively).
DISCUSSION
This study has demonstrated the feasibility of repeated
blood sampling for PCR-based detection of low-level infec-
tions, providing a possible approach to the rapid evaluation of
pre-erythrocytic malaria vaccines. About half of the Gambian
adult men observed over a 28-day period were infected with
P. falciparum detected by a sensitive PCR test, although only
28.8% had parasitemia detectable by microscopy.
Participation in this study involved a major commitment
from the volunteers who were required to take a combination
of drugs to ensure clearance of all asexual and sexual P. fal-
ciparum parasites before the surveillance period commenced.
The drug combination of Lapdap plus artesunate and pri-
maquine proved effective, as only one volunteer had malaria
parasitemia detected by PCR when the surveillance period
began. Lapdap and artesunate were chosen to clear asexual
parasites, as both are short-acting drugs whose blood concen-
trations would have fallen below inhibitory concentrations at
the commencement of surveillance. In addition to the re-
quirement of taking a mixture of antimalarial drugs, volun-
teers were also required to provide a daily finger-prick sample
for 28 consecutive days. It was uncertain whether this would
be acceptable, but > 70% of all possible samples were ob-
tained, and only 21 (20.5%) volunteers withdrew from the
study.
Despite the unexpectedly low immunogenicity of the vac-
cine regimen, we proceeded with the monitoring phase of the
trial. As expected, in view of the low immunogenicity, analy-
sis of efficacy using the primary endpoint of 20 parasites/mL
showed no evidence for protection against infection in the
malaria vaccine group. An opposite effect was suggested
when a higher threshold was used, but this was not statistically
significant. An unexpected finding was the number of low-
parasitemia, short-lived infections detected in volunteers in
the rabies + SP group during the first few days of surveillance.
It is likely that this was caused by parasites released from liver
schizonts before they were eliminated by SP, which is known
to clear parasites less rapidly than other drugs, such as the
artemisins. Further studies will be required to assess if these
observations with SP can be extended to other drugs used for
malaria prophylaxis. It is not clear what the potential effects
of long-term exposure to low levels of blood stage infections
in individuals on long-term drug prophylaxis might be. This
population includes not only long-term non-immune residents
of malaria endemic countries who take regular prophylaxis
but also pregnant women and children receiving intermittent
preventive treatment (IPT). Our data suggest that these in-
FIGURE 2. Ex vivo IFN- ELISPOT responses to P. falciparum
TRAP vaccination, 7 days after final vaccination in the malaria vac-
cine (FFM) and the rabies-vaccinated volunteers. PBMC were stimu-
lated with 6 pools of TRAP peptides containing 7–10 20-mer peptides
overlapping by 10 amino acids. Median values (gray boxes) and in-
dividual values (black spots) are shown.
FIGURE 3. Ex vivo IFN- ELISPOT responses to P. falciparum TRAP and multi-epitope (ME) peptide pools. Responses are from volunteers
in the malaria vaccine (FFM) group 7 days after the final vaccination. Median values (gray boxes) and individual values (black spots) are shown.
Significant differences were observed between traps 1 and 2 (P 0.0058), traps 1 and 5 (P 0.0058), traps 2 and 4 (P 0.003), and traps 3 and
4 (P  0.001). Tests for significance were carried out using the Wilcoxon signed rank test.
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dividuals may be exposed to low-level parasitemia, and it is
possible that this could induce some blood-stage immunity
over time. Indeed, a recent volunteer challenge study with
low doses of blood-stage parasites demonstrated the rapid
development of protective immunity to re-infection.19 In ad-
dition, a study of IPT in Tanzanian infants using SP also
showed that protection lasted for many months longer than
the pharmacological effect of SP, suggesting that some pro-
tective immunity was acquired while on this prophylaxis.20,21
Our findings suggest a possible explanation for these reports.
We have shown that the use of repeated blood sampling
over a short period of time combined with a sensitive PCR
assay is a promising approach to the evaluation of malaria
vaccines that deserves further study, particularly for prelimi-
nary trials in which different doses or vaccine formulations
need to be compared. Reduction of the time of follow-up
needed for vaccine evaluation to a period of 1 month provides
a means of reducing cost and speeding up the evaluation of
new vaccines.
Received July 23, 2006. Accepted for publication October 27, 2006.
Acknowledgments: The authors thank the field team led by Sheriff
Jobe and the volunteers for their patience and understanding; the
safety monitor Ousman Nyan; the head of the MRC Farafenni Field
Station, Sam Dunyo; members of the Data Safety and Monitoring
Board (Diana Lockwood, Richard Hayes, and Automan Gaye); and
trial monitors Ceri McKenna and Carol Hall. The contribution of the
Malaria Vaccine Initiative at PATH to earlier clinical trials of these
vaccines is acknowledged. The Gates Malaria Partnership at the Lon-
don School of Hygiene and Tropical Medicine, which receives sup-
port from the Bill and Melinda Gates Foundation, and the University
of Oxford sponsored the study with additional funding from the
Wellcome Trust.
Disclosure: AVSH is a co-founder of and shareholder in Oxxon
Therapeutics plc, which is developing prime-boost vaccination for
therapeutic applications. AVSH is a Wellcome Trust Principal Re-
search Fellow, and EBI was, at the time of the study, a Gates Malaria
Partnership Training Fellow. EBI is currently in the employment of
the European Malaria Vaccine Initiative.
Authors’ addresses: Egeruan Babatunde Imoukhuede, European
Malaria Vaccine Initiative, 12 Bell House, Ewen Crescent, Tulse Hill,
London, UK, Telephone: +44 (0) 2086748318, Fax: +44 (0)
2032560070, E-mail: ebimoukhuede@hotmail.co.uk. Laura Andrews,
Sarah C. Gilbert, and Adrian V. S. Hill, Wellcome Trust Centre for
Human Genetics, University of Oxford, UK, Telephone: +44 (0) 1865
287592. Paul Milligan, London School of Hygiene and Tropical Medi-
cine, Keppel Street, London, UK, Telephone: +44 (0) 207927 2126.
Tamara Berthoud, Caroline Buckee, and Trudie Lang, Centre for
Clinical Vaccinology & Tropical Medicine, University of Oxford,
UK, Telephone: +44 (0) 1865 857444. Kalifa Bojang, Davis Nwa-
kanma, Jamila Ismaili, Fanta Njie, Saikou Keita, and Maimuna Sowe,
Medical Research Council Laboratories, Fajara, The Gambia, Tele-
phone: +220 4495442. Brian Greenwood, Gates Malaria Partnership,
London School of Hygiene and Tropical Medicine, Keppel Street,
London, UK, Telephone: +44 (0) 207 299 407.
REFERENCES
1. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling
WM, Mensink EJ, Sauerwein RW, 2001. Detection of Plasmo-
dium falciparum malaria parasites in vivo by real-time quan-
titative PCR. Mol Biochem Parasitol 118: 247–251.
2. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D,
Walther M, Gilbert SC, Peto T, Hill AV, 2005. Calculation of
liver-to-blood inocula, parasite growth rates, and preerythro-
cytic vaccine efficacy, from serial quantitative polymerase
chain reaction studies of volunteers challenged with malaria
sporozoites. J Infect Dis 191: 619–626.
3. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM,
Bejon P, Hunt-Cooke A, Bergson G, Sanderson F, Hill AV,
Gilbert SC, 2005. Quantitative real-time polymerase chain re-
action for malaria diagnosis and its use in malaria vaccine clini-
cal trials. Am J Trop Med Hyg 73: 191–198.
4. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A,
Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P,
Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A,
McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001.
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium
falciparum infection in semi-immune adult men in The Gam-
bia: a randomised trial. Lancet 358: 1927–1934.
FIGURE 4. Kaplan-Meier survival estimates showing the probabil-
ity of remaining free of parasitemia during the 28-day follow-up pe-
riod: estimates were done using thresholds of (a) 20, (b) 100, and (c)
1000 parasites/mL followed by a second positive PCR result. The
population used for efficacy analyses included volunteers who re-
ceived a full course of malaria or rabies vaccines, excluding volun-
teers who were PCR-positive on the first day of their surveillance
(Group 1 FFM; Group 2 rabies + SP; Group 3 rabies alone).
This figure appears in color at www.ajtmh.org.
IMOUKHUEDE AND OTHERS492
5. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J,
Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat
Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceup-
pens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez
C, Tornieporth N, Ballou WR, Thompson R, Cohen J, 2004.
Efficacy of the RTS,S/AS02A vaccine against Plasmodium fal-
ciparum infection and disease in young African children: ran-
domised controlled trial. Lancet 364: 1411–1420.
6. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P,
Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart
C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC,
Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR,
2005. Duration of protection with RTS,S/AS02A malaria vac-
cine in prevention of Plasmodium falciparum disease in
Mozambican children: single-blind extended follow-up of a
randomised controlled trial. Lancet 366: 2012–2018.
7. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S,
Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM,
Hill AS, 2004. A randomised, double-blind, controlled vaccine
efficacy trial of DNA/MVA ME-TRAP against malaria infec-
tion in Gambian adults. PLoS Med 1: e33.
8. Dunachie SJ, Walther M, Epstein JE, Keating S, Barthoud T,
Andrews L, Anderson RF, Bejon P, Goonetilleke N, Poulton
I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL,
Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci, DJ,
Hill AV, 2006. A DNA prime-modified vaccinia virus ankara
boost vaccine encoding thrombospodin-related adhesion pro-
tein but not circumsporozoite protein partially protects healthy
malaria-naive adults against Plasmodium falciparum sporozo-
ite challenge. Infect Immun 74: 5933–5942.
9. Greenwood B, 2002. The molecular epidemiology of malaria.
Trop Med Int Health 7: 1012–1021.
10. Mangold KA, Manson RU, Koay ES, Stephens L, Regner M,
Thomson RB Jr, Peterson LR, Kaul KL, 2005. Real-time PCR
for detection and identification of Plasmodium spp. J Clin Mi-
crobiol 43: 2435–2440.
11. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S,
Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen
RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC,
Hill AV, 2005. Enhanced T cell-mediated protection against
malaria in human challenges by using the recombinant poxvi-
ruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad
Sci USA 102: 4836–4841.
12. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S,
Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC,
Poulton I, Dubovsky F, Tierney E, Correa S, Huntcooke A,
Butcher G, Williams J, Sinden RE, Hill AV, 2006. Safety, im-
munogenicity, and efficacy of prime-boost immunization with
recombinant poxvirus FP9 and modified vaccinia virus Ankara
encoding the full-length Plasmodium falciparum circumsporo-
zoite protein. Infect Immun 74: 2706–2716.
13. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T,
Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S,
Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P,
Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE,
Thornton GB, Hill AV, 2005. Safety, immunogenicity and ef-
ficacy of a pre-erythrocytic malaria candidate vaccine, ICC-
1132 formulated in Seppic ISA 720. Vaccine 23: 857–864.
14. Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM,
Berthoud T, Andrews L, Bejon P, Poulton I, Butcher G, Wat-
kins K, Sinden RE, Leach A, Moris P, Tornieporth N,
Schneider J, Dubovsky F, Tierney E, Williams J, Gray Hepp-
ner D Jr, Gilbert SC, Cohen J, Hill AV, 2006. A clinical trial of
prime-boost immunisation with the candidate malaria vaccines
RTS,S/AS02A and MVA-CS. Vaccine 24: 2850–2859.
15. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S,
Gilbert SC, Hill AV, 2005. Differential immunogenicity of
various heterologous prime-boost vaccine regimens using DNA
and viral vectors in healthy volunteers. J Immunol 174: 449–455.
16. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D,
Skinner MA, Gilbert SC, Walraven G, Hill AVS, 2004. Phase
1 evaluation of 3 highly immunogenic prime-boost regimens,
including a 12-month reboosting vaccination, for malaria vac-
cination in Gambian men. J Infect Dis 189: 2213–2219.
17. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC,
Walther M, Laidlaw SM, Peto T, Skinner MA, Gilbert SC, Hill
AV, 2006. Safety of recombinant fowlpox strain FP9 and modi-
fied vaccinia virus Ankara vaccines against liver-stage P. fal-
ciparum malaria in non-immune volunteers. Vaccine 24: 3026–
3034.
18. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, Mc-
Michael AJ, 1997. Rapid effector function in CD8+ memory T
cells. J Exp Med 186: 859–865.
19. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden
M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin
LB, Wilson D, Elliott S, Eisen DP, Weinberg JB, Saul A, Good
MF, 2002. Immunity to malaria after administration of ultra-
low doses of red cells infected with Plasmodium falciparum.
Lancet 360: 610–617.
20. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J,
Tanner M, Mshinda H, Alonso P, 2001. Intermittent treatment
for malaria and anaemia control at time of routine vaccinations
in Tanzanian infants: a randomised, placebo-controlled trial.
Lancet 357: 1471–1477.
21. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M,
Mshinda H, Alonso P, 2005. Intermittent preventive antima-
larial treatment for Tanzanian infants: follow-up to age 2 years
of a randomised, placebo-controlled trial. Lancet 365: 1481–1483.
NEW PCR METHOD FOR MALARIA VACCINE FIELD TRIALS 493
